Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA401 for postherpetic neuralgia
ACTRN12611000822987Phase 2Completed
- Sponsor
- Spinifex Pharmaceuticals
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing EMA401 with Placebo (2 arms). Primary endpoint: Change in mean pain intensity score. Started Aug 2011; status: completed.
02
Drugs
olodanrigan
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ACTRN12611000822987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000822987.